debat around report revolv around ep ramp
impli raw materi fx add increment pressur
stori lower ep midpoint guidanc low
end think fair wonder move piec push return
ecolab-lik result far least market appear
overli concern ecl backdrop ye stock under-perform sinc
earn vs industri strongli
outperform gic sector basic materi valuat ep
remain well within histor rang tweak fx take
revenue/ep estim in-lin revenu impli
organ growth ep estim compar street figur
raw materi cog could increment headwind raw
caustic sanit categori specif raw materi mix
propylen increas sharpli q/q ethylen caustic soda
decreas think net impact like result higher raw pressur
could push margin recaptur note tariff typic sourc local
indirectli expos extent impact commod price gener
fx also got increment wors forecast strengthen
key develop market currenc eur gbp cad weaken em
currenc notabl latam revers expect
ep benefit fx team expect usd strengthen eurusd
ye currenc could turn headwind back half year
bright side organ growth remain healthi range-bound oil
price brent support continu momentum come
best sale qs recent memori organ expect
acceler price need raw increas
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight best-in-class compani
top large-cap idea believ focu
distinct sell model razor/razor blade like
creat endur competit advantag
believ long term could drive ep growth
global econom recoveri reacceler
european margin rebound occur plan
boost potenti accret assum
price-to-earnings multipl ep estim upsid
yield upsid case
growth moder due persist low oil cost
fall plan weak macro recoveri
scenario ep could
downsid case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
compani report thomson reuter streetaccount consensu barclay research
estimateold estimateconsensu estimateseg databarclay estimateold estimateconsensu estimatetot global constant- oper oper rev barclay inc
guidanc ex per share provid callbarclaysestimatesprevi estimatecon bridg reform hurrican invest erp hr revenu recognit adjust segment non- segment metricsfx impact sale gross tax incom guidancechangesy/i improv growth improv growth barclay inc
guidanc commentari earn
guidanc commentari earn
comment call commentary- strong start year show continu good sale momentum first quarter across segment led new busi win new product price remain confid outlook strong year busi momentum improv headwind higher deliv product cost remain signfic throughout year howev believ peak year-on-year basi first quarter system invest cost -- ceo doug baker-expect organ growth segment higher gross margin -volum gain price cost effici action off-set higher deliv product cost similar sg note expect net neutral ep -invest digit technolog -ha increas last year increas help deliv outsizecd valu win signific enterpris custom invest modern backbon erp hr system implement focu continu build top-line momentum -further acceler corpor account win leverag digit platform improv speed market reinvigor institut build gross margin -maintain price momentum off-set impact deliv product cost increas deliv key invest program -product innov custom digit solut capabl talent execut strategi -price -expect go back half year see highest raw pressur includ freight get best price -europ -margin flat expans sinc goal get think see get back track -connect data -more like use drive valu find new opportun custom rather monet data custom site collect data connect cloud work compani like sfdc leverag data margin impact expect materi step-up find effici way retrofit -tariff impact typic look buy sell mitig currency/trad risk -so much direct impact expos indirect impact like everyon els -v diversey -european institut remain competit market diversey aggress price flattish growth stabil expect improv steril without speak busi steril area area focu strateg expect -expect mid-singl digit growth moder gain well stimul modest gain product continu good downstream growth mid/high singl digit better energi growth profit new busi win develop innov product high valu servic offer strong custom relationship -get quickest traction pricing/volum wellchem also sharpest declin see pick inproduct well global recoveri like event expect downstream stay healthi msd rang -margin trajectori -margin certainli turn posit back half year-exit coupl smaller cyclic equip relat busi focus growth stabl part busi growth commentari busi -f continu goodgrowth new busi win offset challeng industri condit realiz custom penetr new busi captur leverag strong innov portfolio continu goodgrowth share gain light heavi mine remain focus strengthen corpor account enterpris sale team develop npi grow new account pipelin continu invest growth area light heavi mine -paper flatin better growth balanc continu global bestpractic price increas focu deliv valu innov solut focu minim water optim total cost growth segment board packag tissu towel pulp -life scienc continu strong growth life scienc sale team continu strengthen product innov develop well new busi pipelin look solid -institut improvedsal growth solid perform reason long-term target continu emphasi drive busi win across region custom -and strong line new innov improv custom result benefit launch smartpow improv expect run-rat year end expect better result apac latam work europ face pressur diversey aggress price continu work aggress region win emerg chain also increas share exist unit busi retent remain strong work aggress win emerg chain increas share exist unit acceler key growth initi start gain traction includ ad corpor account headcountand realign field support launch new warewash laundri platform initi penetr optim program stimul store growth drive share gain lodg long-term care market expans store traffic way use go aggress aroundself-help growth -specialti expect good good strong new busi pipelin on-going invest new product digit offer increas solut custom expect sales/servic forc -healthcar flat organ similar result improv throughout year program sale show good progress europe/fr weaker expect partial due market condit also tough comp technolog delay due regulatori review remain confid long term -pest elimin continu good growth driven market penetr innov servic offer new technolog address key custom global trend make progress global market-focus capabl andfield technolog -colloid technolog revenu unpack nalco -more specialti chemic service-ori grew dd last year focu margin busi long-term guidanc -forward view investor day organ sale growth aoi expans improv still get ep growth-forward view investor day ecl path sale oi margin consist ep growth target algorithm organ growth vol/mix price revenu multi- pipelin target margin expans volum price/innov cost save remain commit happenbi a-rat target leverag vs current past barclay inc
manav patnaik gregori bardi cfa herebi certifi view express research report accur reflect person
view subject secur issuer refer research report part compens
directli indirectli relat specif recommend view express research report
